Back to Results
First PageMeta Content
Bristol-Myers Squibb / Ipilimumab / Cancer immunotherapy / Melanoma / Immunotherapy / CTLA-4 / PD-1 / Steven Rosenberg / Management of cancer / Medicine / Cancer treatments / Immunology


Cancer Immunotherapy This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark History’s path is unchartab
Add to Reading List

Document Date: 2014-01-24 05:34:59

Open Document

File Size: 828,97 KB

Share Result on Facebook

City

Princeton / New Orleans / Houston / Baltimore / /

Company

NEWSFOCUS Pharmaceutical / Medarex / Bristol-Myers Squibb / /

Country

Japan / /

Currency

USD / /

Event

M&A / /

Facility

National Cancer Institute / Memorial Sloan-Kettering Cancer Center / University of Texas MD Anderson Cancer Center / Johns Hopkins University / University of Pennsylvania / Yale University / /

IndustryTerm

biotechnology / CAR therapy / /

MedicalCondition

ve different cancers / cancers / refractory disease / leukemia / tumor / advanced disease / Cancer / tumors / disease / metastatic kidney cancer / advanced melanoma / melanoma / lung cancer / metastatic cancer / deep and rapid tumor / kidney cancer / metastatic melanoma / /

MedicalTreatment

immunotherapies / immunosuppression / cell therapy / immunotherapy / /

Organization

National Cancer Institute / U.S. Food and Drug Administration / Memorial Sloan-Kettering Cancer Center in New York / the University of Pennsylvania / Johns Hopkins University / Yale University / University of Texas / /

Person

Drew Pardoll / James Allison / Carl June / Steven Rosenberg / Mario Sznol / Suzanne Topalian / /

Position

leader / cancer researcher / biologist / /

ProvinceOrState

Texas / New Jersey / Pennsylvania / /

Technology

cell therapy / antibodies / biotechnology / /

URL

http /

SocialTag